Liquid biopsy approach in the management of prostate cancer

      Liquid biopsies examine tumor cells or tumor genomic content in circulating fluids. In advanced prostate cancer which metastasizes frequently to the bone, it is difficult to evaluate underlying and evolving genomic heterogeneity of skeletal metastases for effecting clinical care for which reason liquid biopsies offer an alternate approach. In this review, we will summarize the current state of a wide variety of liquid biopsy-based biomarker assays currently being investigated and developed for managing prostate cancer. We will also highlight technical and clinical challenges and opportunities for translating liquid biopsies into clinical applications.


      ARSIs (androgen receptor signaling inhibitors), AA (abiraterone acetate), AR (androgen receptor), BPH (benign prostatic hyperplasia), CNV (copy number variation), CRPC (castration resistant prostate cancer), CTC (circulating tumor cells), ctDNA (cell-free circulating tumor DNA), DNA (deoxyribo nucleic acid), DRE (digital rectal examination), E (enzalutamide), EpCAM (epithelial cell adhesion molecule), LBD (ligand-binding domain), mCRPC (metastatic castration resistant prostate cancer), mRNAs (messenger ribonucleic acid), miRNAs (micro ribonucleicacid), NGS (next generation sequencing), NHT (novel hormonal therapy), PARP (poly ADP ribose polymerase), PCa (prostate cancer), PSA (prostate specific antigen), qRT-PCR (quantitative reverse transcriptase polymerase chain reaction), RNA (ribonucleic acid), RAF (rapidly accelerated fibrosarcoma)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Translational Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Gomella LG
        The liquid biopsy for prostate cancer 25 years later.
        Can J Urol. 2017; 24: 8693-8694
        • Lin HK
        • Zheng S
        • Williams AJ
        • et al.
        Portable filter-based microdevice for detection and characterization of circulating tumor cells.
        Clin Cancer Res. 2010; 16: 5011-5018
        • Paterlini-Brechot P
        • Benali NL
        Circulating tumor cells (CTC) detection: clinical impact and future directions.
        Cancer Lett. 2007; 253: 180-204
        • Alix-Panabieres C
        • Pantel K
        Challenges in circulating tumour cell research.
        Nat Rev Cancer. 2014; 14: 623-631
        • Simons M
        • Raposo G
        Exosomes–vesicular carriers for intercellular communication.
        Curr Opin Cell Biol. 2009; 21: 575-581
        • Mathivanan S
        • Ji H
        • Simpson RJ
        Exosomes: extracellular organelles important in intercellular communication.
        J Proteomics. 2010; 73: 1907-1920
        • Sun W
        • Luo JD
        • Jiang H
        • Duan DD
        Tumor exosomes: a double-edged sword in cancer therapy.
        Acta Pharmacol Sin. 2018; 39: 534-541
        • Heitzer E
        • Auer M
        • Hoffmann EM
        • et al.
        Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer.
        Int J Cancer. 2013; 133: 346-356
        • Cai X
        • Janku F
        • Zhan Q
        • Fan JB
        Accessing Genetic Information with Liquid Biopsies.
        Trends Genet. 2015; 31: 564-575
        • Robinson D
        • Van Allen EM
        • Wu YM
        • et al.
        Integrative clinical genomics of advanced prostate cancer.
        Cell. 2015; 161: 1215-1228
        • Wang L
        • Dehm SM
        • Hillman DW
        • et al.
        A prospective genome-wide study of prostate cancer metastases reveals association of Wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone.
        Ann Oncol. 2017;
        • Cancer Genome Atlas Research N
        The molecular taxonomy of primary prostate cancer.
        Cell. 2015; 163: 1011-1025
        • Tomlins SA
        • Rhodes DR
        • Perner S
        • et al.
        Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.
        Science. 2005; 310: 644-648
        • King JC
        • Xu J
        • Wongvipat J
        • et al.
        Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis.
        Nat Genet. 2009; 41: 524-526
        • Barbieri CE
        • Baca SC
        • Lawrence MS
        • et al.
        Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.
        Nat Genet. 2012; 44: 685-689
        • Gerlinger M
        • Rowan AJ
        • Horswell S
        • et al.
        Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
        N Engl J Med. 2012; 366: 883-892
        • Vandekerkhove G
        • Chi KN
        • Wyatt AW
        Clinical utility of emerging liquid biomarkers in advanced prostate cancer.
        Cancer Genet. 2017;
        • Xia S
        • Kohli M
        • Du M
        • et al.
        Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer.
        Oncotarget. 2015; 6: 16411-16421
        • He WS
        • Bishop KS
        The potential use of cell-free-circulating-tumor DNA as a biomarker for prostate cancer.
        Expert Rev Mol Diagn. 2016; 16: 839-852
        • Papadopoulou E
        • Davilas E
        • Sotiriou V
        • et al.
        Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer.
        Ann N Y Acad Sci. 2006; 1075: 235-243
        • Delgado-Cruzata L
        • Hruby GW
        • Gonzalez K
        • et al.
        DNA methylation changes correlate with Gleason score and tumor stage in prostate cancer.
        DNA Cell Biol. 2012; 31: 187-192
        • Wu T
        • Giovannucci E
        • Welge J
        • Mallick P
        • Tang WY
        • Ho SM
        Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis.
        Br J Cancer. 2011; 105: 65-73
        • Yin C
        • Luo C
        • Hu W
        • Ding X
        • Yuan C
        • Wang F
        Quantitative and qualitative analysis of circulating cell-free DNA can be used as an adjuvant tool for prostate cancer screening: a meta-analysis.
        Dis Markers. 2016; 20163825819
        • Chun FK
        • Muller I
        • Lange I
        • et al.
        Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer.
        BJU Int. 2006; 98: 544-548
        • Reis IM
        • Ramachandran K
        • Speer C
        • Gordian E
        • Singal R
        Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease.
        Br J Cancer. 2015; 113: 460-468
        • Romanel A
        • Gasi Tandefelt D
        • Conteduca V
        • et al.
        Plasma AR and abiraterone-resistant prostate cancer.
        Sci Transl Med. 2015; 7: 312re10
        • Chi KN
        • Annala M
        • Sunderland K
        • Khalaf D
        • Finch D
        • Oja CD
        • et al.
        A randomized phase II cross-over study of abiraterone + prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).
        J Clin Oncol. 2017; 35: 5002
        • Wyatt AW
        • Azad AA
        • Volik SV
        • et al.
        Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer.
        JAMA Oncol. 2016; 2: 1598-1606
        • Mateo J
        • Carreira S
        • Sandhu S
        • et al.
        DNA-repair defects and olaparib in metastatic prostate cancer.
        N Engl J Med. 2015; 373: 1697-1708
        • Azad AA
        • Volik SV
        • Wyatt AW
        • et al.
        Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer.
        Clin Cancer Res. 2015; 21: 2315-2324
        • Conteduca V
        • Wetterskog D
        • Sharabiani MTA
        • et al.
        Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.
        Ann Oncol: Off J Eur Soc Med Oncol. 2017; 28: 1508-1516
        • Xia Y
        • Huang CC
        • Dittmar R
        • et al.
        Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer.
        Oncotarget. 2016; 7: 35818-35831
        • Lack J
        • Gillard M
        • Cam M
        • Paner GP
        • VanderWeele DJ
        Circulating tumor cells capture disease evolution in advanced prostate cancer.
        J Transl Med. 2017; 15: 44
        • Danila DC
        • Heller G
        • Gignac GA
        • et al.
        Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer.
        Clin Cancer Res. 2007; 13: 7053-7058
        • Scher HI
        • Heller G
        • Molina A
        • et al.
        Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.
        J Clin Oncol. 2015; 33: 1348-1355
        • Hu R
        • Dunn TA
        • Wei S
        • et al.
        Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer.
        Cancer Res. 2009; 69: 16-22
        • Kohli M
        • Ho Y
        • Hillman DW
        • et al.
        Androgen receptor variant AR-V9 is coexpressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance.
        Clin Cancer Res. 2017; 23: 4704-4715
        • Antonarakis ES
        • Lu C
        • Luber B
        • et al.
        Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide.
        J Clin Oncol. 2017; 35: 2149-2156
        • Bernemann C
        • Schnoeller TJ
        • Luedeke M
        • et al.
        Expression of AR-V7 in circulating tumour cells does not preclude response to next generation androgen deprivation therapy in patients with castration resistant prostate cancer.
        Eur Urol. 2017; 71: 1-3
        • Scher HI
        • Graf RP
        • Schreiber NA
        • et al.
        Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer.
        Eur Urol. 2017; 71: 874-882
        • Lamb AD
        • Lawrence MG
        • Sandhu S
        Practical polling for prostate cancer: AR-V7-based treatment selection.
        Eur Urol. 2017; 71: 883-885
        • Taplin ME
        • Balk SP
        Has the time arrived for biomarker-directed therapy in castration-resistant prostate cancer?.
        JAMA Oncol. 2015; 1: 577-579
        • Antonarakis ES
        • Lu C
        • Luber B
        • et al.
        Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer.
        JAMA Oncol. 2015; 1: 582-591
        • Scher HI
        • Lu D
        • Schreiber NA
        • et al.
        Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer.
        JAMA Oncol. 2016; 2: 1441-1449
        • Nakazawa M
        • Lu C
        • Chen Y
        • et al.
        Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.
        Ann Oncol. 2015; 26: 1859-1865
        • Haldrup C
        • Kosaka N
        • Ochiya T
        • et al.
        Profiling of circulating microRNAs for prostate cancer biomarker discovery.
        Drug Deliv Transl Res. 2014; 4: 19-30
        • Chen ZH
        • Zhang GL
        • Li HR
        • et al.
        A panel of five circulating microRNAs as potential biomarkers for prostate cancer.
        Prostate. 2012; 72: 1443-1452
        • Saini S.
        PSA and beyond: alternative prostate cancer biomarkers.
        Cell Oncol (Dordr). 2016; 39: 97-106
        • Bussemakers MJ
        • van Bokhoven A
        • Verhaegh GW
        • et al.
        DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.
        Cancer Res. 1999; 59: 5975-5979
        • Groskopf J
        • Aubin SM
        • Deras IL
        • et al.
        APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer.
        Clin Chem. 2006; 52: 1089-1095
        • Salami SS
        • Schmidt F
        • Laxman B
        • et al.
        Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.
        Urol Oncol. 2013; 31: 566-571
        • Tomlins SA
        • Aubin SM
        • Siddiqui J
        • et al.
        Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.
        Sci Transl Med. 2011; 3: 94ra72
        • Sanda MG
        • Feng Z
        • Howard DH
        • et al.
        Association between combined TMPRSS2:ERG and PCA3 RNA urinary testing and detection of aggressive prostate cancer.
        JAMA Oncol. 2017; 3: 1085-1093
        • Moltzahn F
        • Olshen AB
        • Baehner L
        • et al.
        Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients.
        Cancer Res. 2011; 71: 550-560
        • Martens-Uzunova ES
        • Jalava SE
        • Dits NF
        • et al.
        Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer.
        Oncogene. 2012; 31: 978-991
        • Del Re M
        • Biasco E
        • Crucitta S
        • et al.
        The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients.
        Eur Urol. 2017; 71: 680-687
        • Huang X
        • Yuan T
        • Liang M
        • et al.
        Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer.
        Eur Urol. 2015; 67: 33-41
        • Wang Y
        • Lieberman R
        • Pan J
        • et al.
        miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
        Mol Cancer. 2016; 15: 70
        • Welti J
        • Rodrigues DN
        • Sharp A
        • et al.
        Analytical validation and clinical qualification of a new immunohistochemical assay for androgen receptor splice variant-7 protein expression in metastatic castration-resistant prostate cancer.
        Eur Urol. 2016; 70: 599-608
        • Hornberg E
        • Ylitalo EB
        • Crnalic S
        • et al.
        Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival.
        PLoS One. 2011; 6: e19059
        • Merker JD
        • Oxnard GR
        • Compton C
        • et al.
        Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.
        J Clin Oncol. 2018; 36: 1631-1641
        • Torga G
        • Pienta KJ
        Patient-paired sample congruence between 2 commercial liquid biopsy tests.
        JAMA Oncol. 2018; 4: 868-870